Mgi Pharma — Guilford Pharmaceuticals — Merger or Acquisition (July 2005)
16 slides from Mgi Pharma's merger presentation, Jul 29, 2005
Slide 1: Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company
Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company Banc of America July 29, 2005
Slide 2: Additional Information And Where To Find It
Additional Information And Where To Find It MGI PHARMA intends to file a registration statement on Form S-4 containing a proxy statement/prospectus in connection with the proposed acquisition of Guilford by MGI PHARMA pursuant to the terms of the Agreement and Plan of Merger by and between MGI PHARM
Slide 3: MGI PHARMA: Building A Leading Biopharmaceutical Company
MGI PHARMA Building A Leading Biopharmaceutical Company Revenue potential >$1B within 5 years Aloxi® injection 1H05 sales of $118 M #1 share position in IV 5-HT3 CINV market Product portfolio expansion Pending acquisition of Guilford Pharmaceuticals Aquavan® pivotal program to begin (procedural seda
Slide 4: Guilford Pharmaceuticals: Strategic Rationale
MGI PHARMA Guilford Pharmaceuticals: Strategic Rationale Complimentary Franchises in Oncology & Acute Care Aquavan® Injection Compliments Aloxi® for PONV >$250 million U.S. revenue potential Pivotal program planning underway Gliadel® Wafer Fits current oncology focus 2004 sales totaled $27.7M Augmen
Slide 5: A Leading Biopharmaceutical Company
MGI PHARMA A Leading Biopharmaceutical Company Marketed products Clinical development pipeline Dacogen™ injection (MDS, AML) Saforis™ oral suspension (oral mucositis) Aloxi® injection (PONV) & Aloxi® oral formulation Aquavan® injection (procedural sedation) ZYC101a (cervical dysplasia) Irofulven (HR
Slide 6: The Best in Class 5-HT3 Antagonist for CINV
The Best in Class 5-HT3 Antagonist for CINV Approved for both acute and delayed chemotherapy-induced nausea & vomiting (CINV) Favorable head-to-head trials vs. competitive agents 1H05 sales of $118 million #1 share position in IV CINV market Franchise expansion includes postoperative nausea & vomiti
Slide 7: Post Operative Nausea & Vomiting (PONV)
Post Operative Nausea & Vomiting (PONV) PONV is common with anesthesia and surgical procedures Prevalent in gynecological, abdominal, and ear, nose and throat surgeries Incidence of PONV estimated at 25% to 30% ~ 30 million doses of 5-HT3 RAs used annually in U.S. for PONV Can delay hospital dischar
Slide 8: A Leading Biopharmaceutical Company
MGI PHARMA A Leading Biopharmaceutical Company Marketed products Clinical development pipeline Dacogen™ injection (MDS, AML) Saforis™ oral suspension (oral mucositis) Aloxi® injection (PONV) & Aloxi® oral formulation Aquavan® injection (procedural sedation) ZYC101a (cervical dysplasia) Irofulven (HR
Slide 9: Anti-Cancer Agent with Broad Clinical Activity
Anti-Cancer Agent with Broad Clinical Activity Myelodysplastic syndromes (MDS) MAA accepted for review by EMEA NDA accepted for review by FDA; Sept. 1 PDUFA date Alternative dosing regimen studies ongoing Phase 2 acute myeloid leukemia (AML) trial in elderly patients underway and phase 3 AML trial e
Slide 10: Supportive Care Agent for Oral Mucositis
Supportive Care Agent for Oral Mucositis Proprietary oral formulation (Up-Tec™) of L-glutamine Pivotal phase 3 trial complete in breast cancer patients Primary endpoint met (p=0.026): overall 22% risk reduction (WHO?2) vs. placebo Significant activity in prevention of WHO grade 3 mucositis NDA filin
Slide 11: ZYC101a: Immunotherapeutic for Cervical Dysplasia
ZYC101a Immunotherapeutic for Cervical Dysplasia Immune response therapeutic for treatment of cervical dysplasia, a precancerous condition Phase 2 study completed in 161 patients: In a prospectively defined population of patients under age 25, resolution of high grade dysplasia observed in 70% vs. 2
Slide 12: Irofulven: A Novel, Broadly Active Cytotoxic
Irofulven A Novel, Broadly Active Cytotoxic New chemotherapeutic class with a novel mechanism of action Monotherapy activity in prostate, liver, ovarian and pancreatic cancers Combination activity in prostate, colorectal and thyroid cancers Strong patent position and exclusive worldwide rights Multi
Slide 13: 2005 Financial Guidance
2005 Financial Guidance Provided July 21, 2005 Excluding any impact of the GLFD transaction: Total revenues of $285 million Aloxi sales of $260 million Other product sales, promotion and licensing revenue of $25 million COGS of $97 million SG&A of $80 million Net R&D of $46 million Operating income
Slide 14: Balance Sheet
Balance Sheet (In Thousands) June 30, 2005 ACTUAL Cash and Unrestricted Marketable Investments1 $218,845 Total Assets $439,519 Long-term Debt $260,172 Total Shareholders’ Equity $138,090 Shares Outstanding2 75,703 1. Excludes equity investments 2. Excludes approx. 8 million shares that could issue u
Slide 15: Goals for 2005
Goals for 2005 Revenue: Achieve U.S. sales of Aloxi injection of $260 million Achieve other product sales, promotion and licensing revenue of $25 million Product candidates: Complete pre-launch activities for Dacogen injection for MDS and obtain regulatory approvals Advance the Dacogen injection dev
Slide 16: Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company
Building a Leading Oncology and Acute Care Focused Biopharmaceutical Company Banc of America July 29, 2005
Guilford Pharmaceuticals — Merger or Acquisition (July 2005) on 6ix